GRGwendolyn C. Roux

Gwendolyn C. Roux

*This is an algorithmically generated author record based on publicly available information.

Gwendolyn C. Roux has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Novel ClpP Activators Stimulate ALAS1 Degradation and Inhibition of Heme Synthesis

    by Owen G. Canterbury, Sabrina C.D. Daglish, Emmy Tang, Gwendolyn C. Roux, Maria E. Mrad, Kenglychu Xiong, Paul R. Graves, Jacqueline B. Tiley, Lin Gan, Makiko Yasuda, et al.

    The porphyrias are rare, inherited disorders caused by defects in enzymes of the heme biosynthetic pathway. These deficiencies can result in inefficient heme synthesis and the pathological buildup of toxic intermediates such as 5-aminolevulinic acid (5-ALA) and porphobilinogen (PBG). In hepatic tissues, mitochondrial ALAS1 serves as the first and rate-limiting enzyme in heme biosynthesis; increased expression of ALAS1 by environmental factors contributes to the pathology of acute hepatic porphyria (AHP). Conversely, siRNA-mediated silencing (e.g., Givlaari®) reduces ALAS1 expression and the toxic accumulation of 5-ALA and PBG, validating ALAS1 as a clinical target for AHP. Recently, we identified a class of small molecules that rapidly promote ALAS1 degradation. One of these compounds, ONC201 (dordaviprone, Modeyso®), is an orally available small molecule recently approved by the FDA for the treatment of glioma. We previously showed that ONC201 and related compounds (TR-107, TR-57) activate the mitochondrial matrix protease ClpP in a highly selective manner (hereafter, ClpP agonists). In this study, we demonstrate that ALAS1 is robustly degraded in hepatic and erythroleukemia models in a time-, dose-, and ClpP-dependent manner as confirmed by Western blotting. In parallel with loss of ALAS1, we detected a rapid decline in ClpX, a subunit of ClpXP and proposed regulator of ALAS1. Concomitant with ALAS1 degradation, we observed inhibition of 5-ALA and PBG formation and heme synthesis, demonstrating direct pathway modulation. Importantly, these studies suggest that ClpP agonists are effective small molecules for the reduction of ALAS1 and toxic heme pathway intermediates. In summary, these studies position ClpP agonists, originally developed as anti-cancer agents, as potentially new and fast-acting oral therapeutics for the treatment of acute hepatic porphyrias.

  • Open Access

    Novel ClpP Activators Stimulate ALAS1 Degradation and Inhibition of Heme Synthesis

    by Owen G. Canterbury, Sabrina Cd Daglish, Emmy Tang, Gwendolyn C. Roux, Maria E. Mrad, Paul R. Graves, Jacqueline B. Tiley, Edwin J. Iwanowicz, Lee M. Graves

    The porphyrias are rare, inherited disorders caused by defects in enzymes of the heme biosynthetic pathway. These deficiencies result in incomplete heme synthesis and the pathological buildup of toxic intermediates such as 5-aminolevulinic acid (5-ALA) and porphobilinogen (PBG). In hepatic tissues, ALAS1 serves as the first and rate-limiting enzyme in heme biosynthesis, and siRNA-mediated ALAS1 silencing (e.g., Givlaari®) has validated ALAS1 as a clinical target for acute hepatic porphyria (AHP). Recently we identified a class of small molecules that promote ALAS1 degradation. One of these compounds is ONC201 (dordaviprone, Modeyso®), an orally available small molecule recently approved by the FDA for the treatment of glioma. ONC201 and related compounds (TR-107, TR-57) activate the mitochondrial matrix protease ClpP in a highly selective manner (hereafter, ClpP agonists). Upon ClpP activation, ALAS1 is robustly degraded in a time-, dose-, and ClpP-dependent manner as confirmed by Western blotting in multiple cell models. In parallel with loss of ALAS1, we detected a rapid decline in ClpX, a subunit of ClpXP and proposed regulator of ALAS1. Concomitant with ALAS1 degradation, we observed inhibition of 5-ALA formation and heme synthesis, demonstrating direct pathway modulation. Importantly, these studies demonstrate that ClpP agonists are highly effective and rapidly-acting small molecules for the reduction of ALAS1 and toxic heme pathway intermediates. In summary, these pre-clinical studies position ClpP agonists, originally developed as anti-cancer agents, as potentially new and fast-acting oral therapeutics for the treatment of acute hepatic porphyrias.